Yasunori Kawakita

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Reimagining Early-Phase Clinical Development in Japan: From Regulatory Obligation to Global Acceleration.

Reimagining Early-Phase Clinical Development in Japan: From Regulatory Obligation to Global Acceleration.

Journal: Clinical and translational science

Published: September 12, 2025

Leveraging Model-Informed Drug Development to Predict Asciminib Efficacy in Second-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase.

Leveraging Model-Informed Drug Development to Predict Asciminib Efficacy in Second-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase.

Journal: Clinical pharmacokinetics

Published: August 03, 2025

Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase.

Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase.

Journal: Cancer chemotherapy and pharmacology

Published: June 18, 2025

Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia.

Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia.

Journal: Cancer chemotherapy and pharmacology

Published: August 21, 2024

Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket

Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: April 30, 2023

Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers.

Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers.

Journal: American journal of nephrology

Published: May 11, 2018

Identification of 1-Methyl-N-(propan-2-yl)-N-({2-[4-(trifluoromethoxy)phenyl]pyridin-4-yl}methyl)-1H-imidazole-4-carboxamide as a Potent and Orally Available Glycine Transporter 1 Inhibitor.

Identification of 1-Methyl-N-(propan-2-yl)-N-({2-[4-(trifluoromethoxy)phenyl]pyridin-4-yl}methyl)-1H-imidazole-4-carboxamide as a Potent and Orally Available Glycine Transporter 1 Inhibitor.

Journal: Chemical & pharmaceutical bulletin

Published: November 03, 2016

Discovery of 3-Chloro-N-{(S)-[3-(1-ethyl-1H-pyrazol-4-yl)phenyl][(2S)-piperidine-2-yl]methyl}-4-(trifluoromethyl)pyridine-2-carboxamide as a Potent Glycine Transporter 1 Inhibitor.

Discovery of 3-Chloro-N-{(S)-[3-(1-ethyl-1H-pyrazol-4-yl)phenyl][(2S)-piperidine-2-yl]methyl}-4-(trifluoromethyl)pyridine-2-carboxamide as a Potent Glycine Transporter 1 Inhibitor.

Journal: Chemical & pharmaceutical bulletin

Published: September 02, 2016

Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia.

Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia.

Journal: Psychopharmacology

Published: October 25, 2014

Showing 1-9 of 9

Last Updated: 09/26/2026